Kamada Announces Successful Interim Results Of Phase II Deposition Study With Aerosolized AAT
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced of successful interim results in a Phase II deposition study with its Aerosolized AAT product delivered by PARI's optimized eFlow electronic nebulizer to treat Alpha-1 Deficiency and other respiratory diseases.
Drug Lowers Conversion To Type 2 Diabetes By 81 In Multicenter Study
In a research study of hundreds of patients facing the prospect of developing type 2 diabetes, the oral drug pioglitazone (brand name: Actos ) reduced the rate of conversion to the disease by 81 percent in the active therapy group compared to those taking a placebo, the study leader, Ralph A.
After 1 Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements In Glycaemic Control And Weight
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY), and Alkermes, Inc. (Nasdaq: ALKS) announced results from a 52-week open label clinical study that showed the durable efficacy of exenatide once weekly, a long-acting release formulation of exenatide.
Lower Symptomatic Hypoglycaemia Risk With 'Januvia' trade; Compared To Glipizide On A Background Of Metformin In Type 2 Diabetes Patients
A new analysis presented at the American Diabetes Association (ADA) 68th Annual Scientific Sessions showed treatment with 'Januvia'™ (sitagliptin), Merck & Co., Inc's diabetes medicine, was associated with a 93 percent lower risk of having a confirmed symptomatic hypoglycaemic event on a given day (p=0.
New Data From Head-To-Head Study Confirms Once-Daily Levemir R Is As Effective As Glargine Over A 24-hour Period In Subjects With Type 2 Diabetes
A head-to-head study announced at the American Diabetes Association (ADA) meeting demonstrated that Levemir (insulin detemir [rDNA origin] injection) can be used once daily and had a comparable blood glucose response to insulin glargine over a 24-hour period in patients with type 2 diabetes.
World's Largest Trial Of Intensive Glucose Control In Type 2 Diabetes Finds
The world's largest diabetes trial has shown intensive blood glucose control in type 2 diabetes reduces the risk of complications -- notably a 21% reduction in risk for kidney disease.
Radius Selects First Preclinical Candidate From SARM Discovery Program For The Treatment Of Muscle Loss And Other Musculoskeletal Conditions
Radius Health ("Radius") announced that the company has selected the first lead candidate, RAD140, from its internal nonsteroidal selective androgen receptor modulator ("SARM") discovery program, for full preclinical development as a potential therapy for the treatment of age-related muscle loss (sarcopenia) and other musculoskeletal conditions such as osteoporosis.
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation For Cysteamine In Huntington's Disease
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation for cysteamine bitartrate ("cysteamine") for the treatment of Huntington's disease ("HD").
New Discovery Of Key Difference In Bile Acid Metabolism In Patients With Type 2 Diabetes May Suggest Underlying Disorder
KineMed, Inc., and Daiichi Sankyo, Inc., announced that researchers have discovered a key difference in bile acid metabolism in people with type 2 diabetes which may suggest a newly identified underlying disorder. It has long been known that bile acids help the body absorb fat and cholesterol.
Pharmacyclics Novel Btk Inhibitor Shows Efficacy In Preclinical Models Of Rheumatoid Arthritis And Lymphoma
Pharmacyclics, Inc. (Nasdaq: PCYC) announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal model for rheumatoid arthritis (RA).